Table 1. Baseline clinicopathological characteristics of early- and traditional-onset gastric cancer; SEER database: 2000–2014.
| Parameter | E-gastric cancer (20–39 years) (3,247 patients), n (%) | T-gastric cancer (40+ years) (92,076 patients), n (%) | P value |
|---|---|---|---|
| Race | <0.0001 | ||
| White | 2,237 (68.9) | 65,727 (71.4) | |
| Black | 450 (13.9) | 12,739 (13.8) | |
| Others | 522 (16.1) | 13,152 (14.3) | |
| Unknown | 38 (1.2) | 458 (0.5) | |
| Gender | <0.0001 | ||
| Male | 1,659 (51.1) | 56,154 (61.0) | |
| Female | 1,588 (48.9) | 35,922 (39.0) | |
| Location | <0.0001 | ||
| Cardia | 581 (17.9) | 25,366 (27.5) | |
| Non-cardia | 2,666 (82.1) | 66,710 (72.5) | |
| Grade | <0.0001 | ||
| Well-differentiated | 127 (3.9) | 4,933 (5.4) | |
| Moderately differentiated | 311 (9.6) | 19,077 (20.7) | |
| Poorly differentiated | 1,794 (55.3) | 44,165 (48.0) | |
| Undifferentiated | 97 (3.0) | 1,898 (2.1) | |
| Unknown | 918 (28.3) | 22,003 (23.9) | |
| Histology | <0.0001 | ||
| Intestinal | 78 (2.4) | 7,203 (7.8) | |
| Diffuse | 191 (5.9) | 2,811 (3.1) | |
| Linitis plastica | 55 (1.7) | 839 (0.9) | |
| Adenocarcinoma, NOS | 951 (29.3) | 44,696 (48.5) | |
| Signet ring | 1,108 (34.1) | 14,777 (16.0) | |
| Other histologies | 864 (26.6) | 21,750 (23.7) | |
| Staging* | <0.0001 | ||
| Localized | 629 (19.4) | 24,641 (26.8) | |
| Regional | 794 (24.5) | 26,010 (28.2) | |
| Distant | 1,568 (48.3) | 29,924 (32.5) | |
| Unknown | 256 (7.9) | 11,501 (12.5) | |
| Positive regional lymph nodes | <0.0001 | ||
| Yes | 955 (29.4) | 24,619 (26.7) | |
| No | 1,006 (31.0) | 31,320 (34.0) | |
| Unknown | 1,286 (39.6) | 36,137 (39.2) | |
| Patients with distant metastases** | Not applicable | ||
| Bone | 75 (2.3) | 1,223 (1.3) | |
| Brain | 10 (0.3) | 196 (0.2) | |
| Liver | 135 (4.2) | 4,607 (5.0) | |
| Lung | 72 (2.2) | 1,489 (1.6) | |
| Surgery to the primary | 0.774 | ||
| Yes | 1,351 (41.6) | 38,605 (41.9) | |
| No | 1,830 (56.4) | 51,465 (55.9) | |
| Unknown | 66 (2.0) | 2,006 (2.2) | |
| Chemotherapy | <0.0001 | ||
| Yes | 1,957 (60.3) | 35,146 (38.2) | |
| No/unknown | 1,290 (39.7) | 56,930 (61.8) | |
| Radiotherapy | <0.0001 | ||
| Yes | 714 (22.0) | 19,068 (20.7) | |
| No/unknown | 2,533 (78.0) | 73,008 (79.3) |
*, according to SEER summary staging system; **, among metastatic patients diagnosed after 2010. SEER, The Surveillance, Epidemiology and End Results.